Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA\u00ae (pembrolizumab) i

• click to rate

  Posted by Two Blokes May 22, 2025 - Filed in Stock - 5 views
  
  CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with